Fred Ahlholm's departure as Chief Financial Officer of Minerva Neurosciences, Inc. was reported; the filing names no successor. As of November 6, 2026, Minerva Neurosciences, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 2, 2026 to August 12, 2026, naming 1 appointment and 2 departures (Form 8-K, August 12, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Minerva Neurosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Minerva Neurosciences, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-02 to 2026-08-12. They name 3 people, with 1 appointment and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Minerva Neurosciences, Inc. files it.
Also on the record for Minerva Neurosciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 27, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.1% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by BALYASNY ASSET MANAGEMENT L.P. | 9.99% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G/A, by Farallon Capital Management, L.L.C. | 9.7% of the class | 5%+ stakes | Source |
| July 8, 2026 | Stake report, Schedule 13G/A, by Federated Hermes, Inc. | 17.17% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by JANUS HENDERSON GROUP PLC | 9.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Balyasny Asset Management L.P. | 9.99% of the class | 5%+ stakes | Source |
| February 20, 2026 | Stake report, Schedule 13G, by Coastlands Capital LP | 9.99% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Balyasny Asset Management L.P. | 9.99% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Logos Global Management LP | 9.9% of the class | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G, by Adage Capital Management, L.P. | 6.35% of the class | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G/A, by Dapice Joshua J. | 9.99% of the class | 5%+ stakes | Source |
| December 31, 2025 | Stake report, Schedule 13G, by Vivo Opportunity Fund Holdings, L.P. | 9.99% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Minerva Neurosciences, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Minerva Neurosciences, Inc. and the records around it.
Minerva Neurosciences, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Federated Hermes, Inc. also filed stake reports on 13 other companies: EyePoint (Nov 2026), Arcturus Therapeutics Holdings Inc. (Oct 2026), Forte Biosciences, Inc. (Sep 2026)
- Logos Global Management LP also filed stake reports on 14 other companies: Longeveron Inc. (Sep 2026), ACHIEVE LIFE SCIENCES, INC. (Aug 2026), Yarrow Bioscience, Inc. (Aug 2026)
- Coastlands Capital LP also filed stake reports on 16 other companies: Sutro Biopharma, Inc. (Nov 2026), Bolt Biotherapeutics, Inc. (Nov 2026), Kalaris Therapeutics, Inc. (Oct 2026)
Watch Minerva Neurosciences, Inc.
Get an email when Minerva Neurosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Minerva Neurosciences, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Minerva Neurosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Minerva Neurosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 16 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-12 | In | Chief Accounting Officer | 8-K, 2026-08-12 | ||
| 2026-08-12 | Out | Chief Financial Officer | 8-K, 2026-08-12 | ||
| 2026-04-02 | Out | President | 2026-03-31 | 8-K, 2026-04-02 |
Who leads Minerva Neurosciences, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Fred Ahlholm, departure reported (filed 2026-08-12). No successor is named in these filings.
- Chief Accounting Officer: Anthony Aliquo, appointed (filed 2026-08-12).
- President: Geoffrey Race, departure reported, effective 2026-03-31 (filed 2026-04-02). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Minerva Neurosciences, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Accounting Officer at Minerva Neurosciences, Inc., with the record behind each one.
Find candidates like Chief Accounting Officer at Minerva Neurosciences, Inc.Every change, in the filing's words
Appointed: Anthony Aliquo, Chief Accounting Officer
On August 10, 2026, the Board of Directors (the "Board") of Minerva Neurosciences, Inc. (the "Company") appointed Anthony Aliquo, the Company's Vice President, Controller, as Chief Accounting Officer and principal accounting officer of the Company, effective as of that date.
Departing: Fred Ahlholm, Chief Financial Officer
Effective as of the same date, Fred Ahlholm, Chief Financial Officer of the Company, ceased to serve as the Company's principal accounting officer.
- Mr. Ahlholm will continue to serve as the Company's Chief Financial Officer and principal financial officer.
- Mr. Aliquo, age 39, served as Vice President, Controller for the Company from November 2022 to July 2026, as Controller from August 2021 to November 2022 and as Assistant Controller from September 2020 to August 2021.
- Prior to such, Mr. Aliquo served as an Auditor for BDO USA, P.C. and, before that, he served as an Auditor for Deloitte & Touche, LLP.
- Mr. Aliquo is a CPA with over 10 years of accounting experience.
- He holds a M.S. degree in Accountancy from University of North Carolina Wilmington and a B.S. degree in Mathematics from Saint Michael's College.
- In connection with Mr. Aliquo's appointment, the Board, upon the recommendation of the Compensation Committee of the Board, approved (i) an increase in Mr. Aliquo's annual base salary to $296,696, effective July 1, 2026, and (ii) an increase in his annual performance bonus target to 35% of Mr. Aliquo's annual base salary.
- Other than the foregoing, Mr. Aliquo's compensatory and other arrangements with the Company will continue as in effect prior to his promotion.
Departing: Geoffrey Race, President, effective 2026-03-31
On March 30, 2026, Minerva Neurosciences, Inc., a Delaware corporation (the "Company"), Mind-NRG SARL, a wholly-owned subsidiary of the Company ("Mind-NRG"), and Geoffrey Race, President of the Company, entered into a settlement agreement (the "Settlement Agreement"), pursuant to which Mr. Race resigned from his role as President of the Company and as a Director of Mind-NRG, effective March 31, 2026.
- Under the Settlement Agreement, the Company agreed to make a payment to Mr. Race, in lieu of the 12-month notice entitlement provided by Mr. Race's Employment Agreement with Mind-NRG, dated as of August 1, 2016 (as amended by that certain First Amendment to Employment Agreement, effective October 11, 2021), which payment consists of (i) a one-time payment in the amount of his annual salary, (ii) 12-months' pension contributions and (iii) a pro-rated portion of his 2026 bonus-entitlement.
- With respect to Mr. Race's outstanding stock options to purchase shares of common stock of the Company granted pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan (the "Plan"), the Company agreed to treat all such options as fully vested effective as of March 31, 2026, and to extend the period during which Mr. Race may exercise such options until midnight U.S. Eastern Time on January 1, 2030, after which time the options will lapse and cease to be exercisable.
- Also on March 30, 2026, the Company entered into a consultancy agreement (the "Consultancy Agreement") with Mr. Race.
Tools for this story
Each opens in a new tab, filled in for Minerva Neurosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.